Amgen Submits Application In Europe To Expand Indication Of Kyprolis® (carfilzomib) For The Treatment Of Relapsed Multiple Myeloma

Application Based on Pivotal Head-to-Head ENDEAVOR Study Showing Kyprolis Plus Dexamethasone Doubled Progression-Free Survival Compared to Velcade® (Bortezomib) Plus Dexamethasone THOUSAND OAKS, Calif., Dec. 5, 2015 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the submission to the European Medicines Agency (EMA) of a Variation to the Marketing Authorization Application (MAA) to expand the indication for Kyprolis® (carfilzomib) in combination with dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The application is based on results from the Phase 3 head-to-head ENDEAVOR study in which patients with multiple my...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news